AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

NEURIZON THERAPEUTICS LTD

0.076

-0.002-2.56%

Volume:338.22K

Turnover:25.70K

Market Cap:59.60M

PE:-4.32

High:0.080

Open:0.076

Low:0.073

Close:0.078

52wk High:0.165

52wk Low:0.053

Shares:784.22M

Float Shares:351.37M

Volume Ratio:0.30

T/O Rate:0.10%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.018

EPS(LYR):-0.018

ROE:-137.94%

ROA:-45.31%

PB:4.68

PE(LYR):-4.32

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

ASX Runners of the Week: Iondrive, Australasian, Aruma & Neurizon

The West Australian

Neurizon Therapeutics Redeems 1 Million Convertible Notes From Obsidian for Over $1 Million; Shares Fall 8%

MT Newswires Live

Neurizon Therapeutics Secures NIH Grant to Support Investigational ALS Treatment; Shares Up 31%

MT Newswires Live

Neurizon Therapeutics Appoints Chris Bremer as Chief Executive Officer

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/stock/NUZ.AU"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"NUZ.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"NUZ.AU\",,,,,undefined,":{"symbol":"NUZ.AU","market":"AU","secType":"STK","nameCN":"NEURIZON THERAPEUTICS LTD","latestPrice":0.076,"timestamp":1789107120000,"preClose":0.078,"halted":0,"volume":338216,"delay":0,"changeRate":-0.025641025641025664,"nameEN":"NEURIZON THERAPEUTICS LTD","floatShares":351374969,"shares":784215600,"eps":-0.0176,"marketStatus":"Not Yet Opened","change":-0.002,"latestTime":"09-11 16:12:00 AEST","open":0.076,"high":0.08,"low":0.073,"amount":25700,"amplitude":0.089744,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.0176,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1789344000000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.078,"openAndCloseTimeList":[[1789084800000,1789106400000]],"volumeRatio":0.30408397279174776,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"NUZ.AU","preClose":0.078,"auctionPrice":0.076,"auctionVolume":23809,"auction":3,"marketStatus":"盘后竞价","timestamp":1789106402670}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"NUZ.AU\",,,,,undefined,":{"symbol":"NUZ.AU","floatShares":351374969,"roa":"-45.31%","roe":"-137.94%","lyrEps":-0.0176,"volumeRatio":0.30408397279174776,"shares":784215600,"dividePrice":0,"high":0.08,"amplitude":0.089744,"preClose":0.078,"low":0.073,"week52Low":0.053,"pbRate":"4.68","psRate":"3.39","week52High":0.165,"institutionHeld":0,"latestPrice":0.076,"eps":-0.0176,"divideRate":0,"volume":338216,"delay":0,"ttmEps":-0.0176,"open":0.076,"prevYearClose":0.085,"prevWeekClose":0.076,"prevMonthClose":0.056,"prevQuarterClose":0.06,"fiveDayClose":0.056,"twentyDayClose":0.062,"sixtyDayClose":0.062,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NUZ.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NUZ.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NUZ.AU\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2666154630","title":"ASX Runners of the Week: Iondrive, Australasian, Aruma & Neurizon","url":"https://stock-news.laohu8.com/highlight/detail?id=2666154630","media":"The West Australian","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666154630?lang=en_us&edition=fundamental","pubTime":"2026-09-11 05:57","pubTimestamp":1789077437,"startTime":"0","endTime":"0","summary":"The Bulls N’ Bears ASX Runner of the Week is... Iondrive, after an economic evaluation of its IONSolv technology showed a US$243 million (A$338 million) net present value for just a single proprietary module.","market":"hk","thumbnail":"https://images.thewest.com.au/publication/C-22857359/f3ba145e5bde0aa97d4b38a2ae55d7e52f82c4d9.jpg","type":0,"news_type":0,"thumbnails":["https://images.thewest.com.au/publication/C-22857359/f3ba145e5bde0aa97d4b38a2ae55d7e52f82c4d9.jpg"],"rights":{"source":"thewest_stock","url":"https://thewest.com.au/business/bulls-n-bears/asx-runners-of-the-week-iondrive-australasian-aruma-neurizon-c-22857359","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://thewest.com.au/business/bulls-n-bears/asx-runners-of-the-week-iondrive-australasian-aruma-neurizon-c-22857359","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"thewest_stock","symbols":["CRSH","ELOL","TSLI","BK7095","FXZ","COPP","TLA","ICOP","TSDD","XME","07766","TSLG","MVPS","TSLW","NUZ.AU","UYM","TSLP","TSLR","CPER","PLS.AU","TESL","TSLL","09766","TSL","PICK","09366","BK4535","07366","CPXR","TSLQ","CRIT","NPV","TSYY","A8G.AU","BK4516","TSII","AAJ.AU","COPJ","BK7104","TSLY","TSLO","BK7507","TSLS","TESC","TSLT","TSLZ","TEST","BK7096","ION.AU","VMS.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666551483","title":"Neurizon Therapeutics Redeems 1 Million Convertible Notes From Obsidian for Over $1 Million; Shares Fall 8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2666551483","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666551483?lang=en_us&edition=fundamental","pubTime":"2026-09-10 10:26","pubTimestamp":1789007198,"startTime":"0","endTime":"0","summary":"Neurizon Therapeutics  agreed to redeem 1 million convertible notes held by Obsidian for a total consideration of about $1.2 million, with Obsidian agreeing not to sell Neurizon shares for two months following completion, according to a Thursday Australian bourse filing.Upon completion, Obsidian will hold 750,000 convertible notes, the filing added.Neurizon added that it remains fully funded through to the topline readout of the HEALEY ALS Platform Trial and completion of the study.The company's shares fell past 8% in recent Thursday trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NUZ.AU","BK4539","BK4139","BK7096","LENZ","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666301515","title":"Neurizon Therapeutics Secures NIH Grant to Support Investigational ALS Treatment; Shares Up 31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2666301515","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666301515?lang=en_us&edition=fundamental","pubTime":"2026-09-09 11:09","pubTimestamp":1788923345,"startTime":"0","endTime":"0","summary":"Neurizon Therapeutics  said the US National Institutes of Health  has awarded a multimillion-dollar, multi-year grant to support an expanded access protocol  for its investigational amyotrophic lateral sclerosis  therapy NUZ-001, according to a Wednesday filing with the Australian bourse.The program is expected to provide up to 200 ALS patients who are ineligible for clinical trials with access to NUZ-001 for up to 96 weeks, alongside the ongoing phase two and three Healey ALS platform trial, per the filing.The company will serve as the regulatory sponsor and provide the drug, while the Healey and AMG Center for ALS will oversee clinical operations, the filing said.The EAP is fully funded by the NIH and is expected to involve about 20 clinical sites across the US, alongside a national virtual site, with enrolment targeted to begin in the first quarter of 2027, subject to regulatory and operational approvals, the filing added.The company's shares jumped 31% in recent Wednesday trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4539","LENZ","BK4007","BK4139","BK7096","NUZ.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665986393","title":"Neurizon Therapeutics Appoints Chris Bremer as Chief Executive Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2665986393","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665986393?lang=en_us&edition=fundamental","pubTime":"2026-09-07 09:41","pubTimestamp":1788745278,"startTime":"0","endTime":"0","summary":"Sept 7 (Reuters) - Neurizon Therapeutics Ltd::*NEURIZON APPOINTS CHIEF EXECUTIVE OFFICER*APPOINTS CHRIS BREMER AS CEO EFFECTIVE 1 OCTOBER 2026*Further company coverage: NUZ.AX* ((reuters.briefs@thomso","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260907:nRSD5GZz4J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUZ.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":8,"pageCount":1,"totalSize":32,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/NUZ.AU\",params:#limit:6,delay:true,,,undefined,":[]}}